NEW YORK, July 31, 2013 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC
announces that a securities class action has been filed in the
United States District Court for the Middle District of
Florida on behalf of those who
purchased shares of Accentia Biopharmaceuticals, Inc.
("Accentia") (OTC: ABPI) or Biovest International, Inc. ("Biovest")
(OTCQB:BVTIQ), a majority-owned subsidiary of Accentia during the
period between July 26, 2008 through
August 14, 2012 inclusive (the "Class
Period").
The Complaint charges Accentia and certain officers and
directors of Accentia and Biovest with violations of federal
securities laws. The Complaint alleges that the FDA informed
Biovest that the results of a Phase III clinical trial for
BiovaxID, a potential vaccine for the treatment of non-Hodgkin's
lymphoma, did not support an application for approval of BiovaxID.
Contrary to the FDA advice, Defendants made numerous
statements in press releases and securities filings that gave the
misleading impression that BiovaxID vaccine was on the path to FDA
approval.
Plaintiff seeks to recover damages on behalf of shareholders who
purchased common stock of the companies during the Class Period
described above.
No Class has yet been certified in the above action. If you wish
to review a copy of the Complaint, to discuss this action, or have
any questions, please contact Peretz
Bronstein, Esq. or his Investor Relations Coordinator
Eitan Kimelman of Bronstein, Gewirtz
& Grossman, LLC at 212-697-6484 or via email info@bgandg.com.
Those who inquire by e-mail are encouraged to include their mailing
address and telephone number. September 30,
2013 is the deadline for investors to seek a lead plaintiff
appointment. Your ability to share in any recovery doesn't
require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
SOURCE Bronstein, Gewirtz & Grossman, LLC